the Study of Diabetes meeting in Lisbon, Portugal in September, 2011. References 1 Drucker DJ, Nauck MA. The incretin system: glucagon-like  peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696–705. 2 Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide  (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004; 117: 77–88. 3 Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD.  Eﬀ  ects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628–35. 4 DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD.  Eﬀ  ects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092–100. 5 Kendall DM, Riddle MC, Rosenstock J, et al. Eﬀ  ects of exenatide